REGENXBIO Inc. (RGNX)

REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting

REGENXBIO Inc. (RGNX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

REGENXBIO to Participate in Upcoming Investor Conferences

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)

RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy

Regenxbio: Sell-Off On Hunter Setback Presents A Risky Buy Opportunity

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli

RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO Inc. Following Clinical Hold

Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial

FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome

REGENXBIO Announces Regulatory Update on RGX-121 for MPS II

Regenxbio's Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade)

REGENXBIO Q2 Earnings Call Highlights

REGENXBIO Inc. (RGNX) Q2 2026 Earnings Call Transcript

Regenxbio (RGNX) Beats Q2 Earnings and Revenue Estimates

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights

New Strong Sell Stocks for July 23rd